Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.
A La CaRT: Australasian Laparoscopic Cancer Of The Rectum Trial. A Phase III Prospective Randomised Trial Comparing Laparoscopic-assisted Resection Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$599,054.00
Summary
The major treatment for rectal cancer is surgical removal of tumour with a large cut through the abdomen. There is a newer, less invasive procedure known as laparoscopic resection which enables the same surgery to be performed using a scope inserted in the abdomen and another smaller incision for removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure. Patients on the trial will be given either laparoscopi
A La CaRT: Australasian Phase III Randomised Trial Comparing Laparoscopic-assisted Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$974,440.00
Summary
The current major treatment for rectal cancer is surgical removal of the cancer. This type of surgery requires a large cut through the abdomen for removal of the cancer. There is a newer, less invasive procedure known as laparoscopic resection enabling the same surgery by using a scope inserted in the abdomen along with a smaller incision to allow removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure.
POSNOC (Positive Sentinel Node – A Randomised Trial Of Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance Or Axillary Radiotherapy)
Funder
National Health and Medical Research Council
Funding Amount
$1,223,428.00
Summary
POSNOC (POsitive Sentinel NOde – adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy) will address the key unresolved challenge in breast cancer surgery. A controversial US trial, ACOSOG Z0011, indicates that many breast cancer patients with limited disease in the sentinel node can safely avoid further nodal surgery. This would be a major advance, but there is widespread doubt that the results are broadly applicable. POSNOC will clarify this key issue.
Germ Cell Development In The Postnatal Testis: The Key To Early Surgery To Prevent Infertility And Malignancy In Cryptorchidism
Funder
National Health and Medical Research Council
Funding Amount
$725,326.00
Summary
The germ cells have been studied very extensively before birth or after puberty, but little is known about what happens shortly after birth. In children with undescended testes, early germ cell development is deranged, and this may be the key to find the right time for surgery to prevent subsequent infertility and risk of cancer. This project proposes some novel hypotheses to explain this and the studies aim to obtain the evidence to support surgery in the first 3-6 months of life..
Detection Of Liver And Renal Function Abnormalities In The Australian & New Zealand Population Of Fontan Patients
Funder
National Health and Medical Research Council
Funding Amount
$345,080.00
Summary
Children born with complex heart defects and only one pumping chamber can now live into adulthood with an operation called the Fontan procedure. As this operation has only existed for 40 years, the long-term expectations for these children and young adults are still unclear, and their population is growing every year. There is now evidence that they may suffer from liver and kidney failure. This project will identify the severity of liver and kidney damage in our population of Fontan patients.